Yoshitaka Sakurai
Hongo, 1130033, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Pharmacotherapy as a catalyst for behaviour change.
Journal: BMJ (Clinical research ed.)
Published: April 01, 2026
GLP-1R R131Q links long-range conformational remodeling to cellular stress phenotypes.
Journal: Journal of molecular graphics & modelling
Published: April 01, 2026
Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.
Journal: Endocrinology, diabetes & metabolism
Published: February 23, 2026
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
Journal: Circulation
Published: July 11, 2024
Dissociating the metabolic and tumor-suppressive activity of p53.
Journal: Trends in endocrinology and metabolism: TEM
Published: June 30, 2024
Ultra-processed foods cause weight gain and increased energy intake associated with reduced chewing frequency: A randomized, open-label, crossover study.
Journal: Diabetes, obesity & metabolism
Published: June 23, 2024
Salivary glycated albumin could be as reliable a marker of glycemic control as blood glycated albumin in people with diabetes.
Journal: Diabetes research and clinical practice
Published: June 14, 2024
Bi-weekly Glycated Albumin Measurement was Useful to Encourage Behavioral Changes in People with Type 2 Diabetes Mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 01, 2023
Associations of sleep quality with the skeletal muscle strength in patients with type 2 diabetes with poor glycemic control.
Journal: Journal of diabetes investigation
Published: December 07, 2022
Evaluation of glycated albumin levels in tears and saliva as a marker in patients with diabetes mellitus.
Journal: Diabetes research and clinical practice
Published: June 24, 2022
The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
Journal: Pharmacology research & perspectives
Published: November 09, 2021
Last Updated: 09/26/2026